SupplySide West 2021: Dr. John Deaton Presents DE111 Findings
Dr. John Deaton presented the DE111 clinical study findings at Supply Side West in Las Vegas. This study investigates spore germination under in-vivo conditions in the human small intestine. The findings aim to enhance understanding of probiotics and their health benefits.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
First-ever clinical study on spore germination in human small intestine.
Dr. John Deaton presented the findings at Supply Side West.
Research reveals the probiotic effects of Bacillus subtilis DE111.
Get featured
Want to get featured in MarketScale Sciences?
Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.
The Deerland team recently attended Supply Side West in Las Vegas! At the show, Dr. John Deaton presented the findings of the first-ever clinical study to directly investigate spore germination under real-time in-vivo conditions in the human small intestine.
For those that weren’t able to attend, we have brought the presentation to you!
“Growing is Knowing: New Research Reveals Clear Evidence of Germination of the Probiotic Bacillus subtilis DE111®️”
- About Bacillus subtilis DE111®️
- Proving Germination in the Small Intestines
- Study Design and Outcomes
- Implications of Germination in the Small Intestines
- Clinical Outcomes in Microbiome & Immune Support
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
